1. Home
  2. Products
  3. Customized ADCs
  4. CD22
  5. Anti-CD22-DIBO-doxorubicin ADC

Anti-CD22-DIBO-doxorubicin ADC (CAT#: ADC-W-339)

This ADC product is comprised of an anti-CD22 monoclonal antibody conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • CD22
  • Alternative Names
  • CD22; CD22 molecule; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2;
  • Target Entrez Gene ID
  • 933
  • Overview
  • CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.
    CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.
  • Overview
  • Humanized Anti-CD22 Antibody, Inotuzumab
  • Generic name
  • Inotuzumab
  • Species Reactivity
  • Human
  • Name
  • DIBO (dibenzylcyclooctynol)
  • Name
  • doxorubicin
  • Description
  • Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-339. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-2530 Anti-CD22-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2534 Anti-CD22 (Pinatuzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-484 Anti-CD22-MCC-DM1 ADC-11 MCC (Maleimidomethyl cyclohexane-1-carboxylate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-2535 Anti-CD22 (Pinatuzumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2528 Anti-CD22-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-340 Anti-TNFRSF8-DIBO-doxorubicin ADC-12 DIBO (dibenzylcyclooctynol) doxorubicin
CAT# Product Name Linker Payload
ADC-W-412 Anti-ERBB2 (Trastuzumab)-NGM-doxorubicin ADC NGM doxorubicin
ADC-W-463 Anti-FUT3-Mc-Dox ADC Mc (maleimidocaproyl) Doxorubicin
ADC-W-502 Anti-EGFR-SMCC-Dox ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) Doxorubicin
ADC-W-378 Anti-CD74-hindered disulfide-Doxorubicin ADC hindered disulfide doxorubicin
ADC-W-423 Anti-FUT3-hydrazone-doxorubicin ADC hydrazone doxorubicin

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.